Summary: Purpose: Stiripentol (STP) is currently an efficient drug for add-on therapy in infantile epilepsies because it improves the efficacy of antiepileptic drugs (AEDs) through its potent inhibition of liver cytochromes P450.
Quilichini , Pascale P.
core
Mitochondrial dysfunction and senescence accompany glioblastoma cell death triggered by a putative metabolic inhibitor. [PDF]
Eur J PharmacolYadav A +6 more
europepmc +1 more source
Fenfluramine for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. [PDF]
Aust Prescreuropepmc +1 more source
Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies. [PDF]
EpilepsiaPotschka H, Pérez-Pérez D.
europepmc +1 more source
Microglial activation is inhibited by selective anti-seizure medications. [PDF]
Inflamm ResPlatow RJ +5 more
europepmc +1 more source
Uncovering a feedback loop in glioblastoma that reinforces stemness and immunosuppression. [PDF]
J Clin InvestBasakis P, Shih LK, Li J, Brat DJ.
europepmc +1 more source
Stiripentol safety profile and efficacy in cases of SCN1A-related Dravet syndrome, multi-center experience, Saudi Arabia. [PDF]
Neurosciences (Riyadh)Almuatiri AM +14 more
europepmc +1 more source
Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study. [PDF]
Dev Med Child NeurolMarc R +9 more
europepmc +1 more source
Familial SCN1A-Related Epilepsy in Palestinian Siblings: Challenges of Genetic Testing in Resource-Limited Settings: A Case Report. [PDF]
Clin Case RepAbu Hetta A +5 more
europepmc +1 more source